Cargando…

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC

SIMPLE SUMMARY: One of the most incredible advances in nuclear medicine is early detection of neuroendocrine tumors, which leads to appropriate and expedient treatment pathways. Advances made with somatostatin analogue derivatives radiolabeled with Gallium-68 clarified the paths of diagnosis and tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vahidfar, Nasim, Farzanehfar, Saeed, Abbasi, Mehrshad, Mirzaei, Siroos, Delpassand, Ebrahim S., Abbaspour, Farzad, Salehi, Yalda, Biersack, Hans Jürgen, Ahmadzadehfar, Hojjat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027354/ https://www.ncbi.nlm.nih.gov/pubmed/35454822 http://dx.doi.org/10.3390/cancers14081914

Ejemplares similares

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

Synthesis of DOTA-pyridine chelates for (64)Cu coordination and radiolabeling of αMSH peptide
por: Yang, Hua, et al.
Publicado: (2021)

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model
por: Ullrich, Martin, et al.
Publicado: (2016)

Theranostic Advances in Breast Cancer in Nuclear Medicine
por: Vahidfar, Nasim, et al.
Publicado: (2021)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

Single-Center Comparison of [(64)Cu]-DOTAGA-PSMA and [(18)F]-PSMA PET–CT for Imaging Prostate Cancer
por: Mirzaei, Siroos, et al.
Publicado: (2021)

[(64)Cu]‐labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice
por: Schjoeth‐Eskesen, Christina, et al.
Publicado: (2015)

Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for the (64)Cu-Labelling of Immunoconjugates
por: Maisonial-Besset, Aurélie, et al.
Publicado: (2022)

Potential Production of Theranostic Boron Nitride Nanotubes ((64)Cu-BNNTs) Radiolabeled by Neutron Capture
por: Silva, Wellington Marcos, et al.
Publicado: (2021)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Somatostatin-based radiotherapy with [(90)Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
por: Marincek, Nicolas, et al.
Publicado: (2013)

PACE4-Based Molecular Targeting of Prostate Cancer Using an Engineered (64)Cu-Radiolabeled Peptide Inhibitor()()
por: Couture, Frédéric, et al.
Publicado: (2014)

Imaging of atherosclerosis with [(64)Cu]Cu-DOTA-TATE in a translational head-to-head comparison study with [(18)F]FDG, and Na[(18)F]F in rabbits
por: Grandjean, Constance E., et al.
Publicado: (2023)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Positron Emission Tomography Imaging of CD105 Expression with a (64)Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA
por: Zhang, Yin, et al.
Publicado: (2011)

Evaluation of [(64)Cu]Cu-NOTA-PEG(7)-H-Tz for Pretargeted Imaging in LS174T Xenografts—Comparison to [(111)In]In-DOTA-PEG(11)-BisPy-Tz
por: Poulie, Christian B. M., et al.
Publicado: (2021)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Comparative Saturation Binding Analysis of (64)Cu-Labeled Somatostatin Analogues Using Cell Homogenates and Intact Cells
por: Ullrich, Martin, et al.
Publicado: (2023)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Dose predictions for [(177)Lu]Lu-DOTA-panitumumab F(ab′)(2) in NRG mice with HNSCC patient-derived tumour xenografts based on [(64)Cu]Cu-DOTA-panitumumab F(ab′)(2) – implications for a PET theranostic strategy
por: Ku, Anthony, et al.
Publicado: (2021)

(64)Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
por: Higashikawa, Kei, et al.
Publicado: (2014)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Occupational radiation exposure assessment during the management of [(68)Ga]Ga-DOTA-TOC
por: Riveira-Martin, Mercedes, et al.
Publicado: (2022)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
por: Han, Zheng, et al.
Publicado: (2019)

Toc64, a New Component of the Protein Translocon of Chloroplasts
por: Sohrt, Karen, et al.
Publicado: (2000)

Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog
por: Costa, Ricardo, et al.
Publicado: (2013)

Optimization of (177)Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
por: Cankaya, Aylin, et al.
Publicado: (2023)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides in Patients with Neuroendocrine Tumours
por: Gospavic, Radovan, et al.
Publicado: (2016)

Towards integration of (64)Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer
por: Jarrett, Angela M., et al.
Publicado: (2020)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
por: Yordanova, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jts1qpfu4v06villoq9222rfsf